Orforglipron vs GHK
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
OrforglipronSkin & CosmeticAnti-Aging & Longevity
GHK- Summary
- Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
- GHK is the natural tripeptide (Gly-His-Lys) released from human albumin that activates tissue remodeling, collagen synthesis, and anti-aging gene expression. The copper-free form is the biological signaling molecule; it chelates copper in tissue to form GHK-Cu but also has independent biological activity.
- Half-Life
- ~12 hours (once-daily oral dosing)
- Extremely short as free peptide; tissue binding extends local effects
- Admin Route
- Oral
- SubQ, Topical, Oral
- Research
- —
- —
- Typical Dose
- 12 mg → 24 mg → 36 mg → 45 mg
- 100–500 mcg
- Frequency
- Once daily
- Daily or 5x per week
- Key Benefits
- Oral pill — no injections required
- Once-daily dosing without food restrictions (unlike oral semaglutide)
- Up to 9.4% body weight reduction in Phase 2 at 36 weeks
- Significant HbA1c reduction in type 2 diabetes trials
- Small-molecule stability — no cold chain requirements
- Broadens access for injection-averse patients
- Potential class-defining convenience advantage over injectable GLP-1s
- Stimulates collagen and extracellular matrix synthesis
- Activates tissue repair gene expression programs
- Anti-aging: reverses 57% of age-related gene changes
- Antioxidant and anti-inflammatory
- Wound healing and skin barrier repair
- Improves skin laxity, texture, and radiance
- Neuroprotective (stimulates NGF, BDNF)
- Anti-fibrotic in liver and lung models
- Side Effects
- Nausea (most common, dose-dependent)
- Vomiting
- Diarrhea
- Decreased appetite
- +2 more
- Excellent safety profile (naturally occurring peptide)
- Rare: mild injection site reaction (SC)
- No significant adverse effects identified in research
- Stacks With
- —
- —